Posted by Michael Wonder on 25 Oct 2022
Hugel Aesthetics receives FDA acceptance of BLA resubmission for letibotulinumtoxinA for injection for glabellar lines
25 October 2022 - PDUFA goal date set for 6 April 2023.
Hugel America announced today the acceptance of its biologics license application for letibotulinumtoxinA, by the US FDA.
